Navigation Links
TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Date:12/5/2011

MALVERN, Pa., Dec. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead Smac mimetic drug candidate, TL32711, in elderly patients with acute myelogenous leukemia (AML). The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.

"In preclinical studies on primary human AML samples, TL32711 inhibits the growth and survival of AML cells as demonstrated in colony forming assays and a xenotransplantation model of the disease," said Martin Carroll, M.D., of the Hospital of the University of Pennsylvania. "These encouraging data along with TL32711's novel mechanism of action support its clinical development for AML where new treatment options are needed especially for the elderly."

"This clinical study represents another important step in advancing TL32711 as a potential treatment for AML and supports our goal of providing improved therapies for patients with cancer," said John Gill, TetraLogic's President and Chief Executive Officer.  "The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins (IAPs) represents a new broadly applicable approach to treat cancers that are normally resistant to therapies, including AML."

About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological mali
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... 26, 2015 After litigating and negotiating ... relating to P2i United States patent ... in the United States without any ... of either party. As a result of the parties, settlement, ... California dismissed the case without prejudice. ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial ... with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to ... regulatory pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... In an address to,shareholders at the company,s ... ) Chairman and CEO David B. Snow Jr. ... designed to deliver strong,continuing earnings growth through 2008 ... specialty pharmacy to retaining and winning,customers, and advanced ...
... May 22 /PRNewswire-FirstCall/ - In accordance with the,terms ... Inc.,"Atrium" (TSX: ATB) today announced that it has ... Chemicals division for total proceeds of,US$166.4 million in ... is now a health and nutrition pure-play and ...
... CT Injection System Technology Detects Extravasations during CT ... ... MEDRAD, INC., announced today,that its XDS(TM) Extravasation Detector has ... a technology that aids in the,detection of leaking intravenous contrast ...
Cached Biology Technology:Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 2Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 3Medco CEO to Shareholders: Delivering Results, Driving Shareholder Value 4MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 2MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award 3
(Date:8/24/2015)... 2015 The consulting company Frost & ... manufacturer DERMALOG and its customized solutions and products for ... of the Year Award". DERMALOG is particularly successful with a ... -Cross reference: Picture is available at AP Images ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
Breaking Biology News(10 mins):Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... fond of talking about it as are politicians, economists ... The problem is that the term sustainability can refer ... at the Technische Universitaet Muenchen have shed light on ... science they have managed to give the term "sustainability" ...
... School of Medicine found that women may have a slightly higher ... acute coronary syndrome (ACS), but that these differences appear to be ... study, published in the August 26, 2009 issue of the ... however that overall there was no significant difference in mortality observed ...
... use wireless sensors, which can monitor chemical processes or ... wireless network. Still, many facilities that could benefit ... use a wired network instead, because the reliability, speed ... do not meet their needs. The U.S. ...
Cached Biology News:New tools for sustainable farming 2New tools for sustainable farming 3Study finds women slightly more likely to die than men in the 30 days following a heart attack 2SRNL, automakers to develop high-performance wireless sensors networks 2SRNL, automakers to develop high-performance wireless sensors networks 3
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: